IKS applies laboratory expertise to motorcycling
Sets up racing team and uses XiltriX to monitor racing performance of rider Mervyn Verploegen
According to IKS md Stephen Tierney, this is not just the usual sponsorship arrangement: IKS will be applying the expertise accumulated in more than 20 years of laboratory monitoring to improve racing performance.
‘We’re delighted to be able to help this young talent advance his sporting career and to support his family, who are very much involved,’ he said. ‘Unusually in such situations, though, we can also contribute technically by applying the technology employed in our XiltriX laboratory monitoring systems to measuring parameters such as tyre temperature and pressure that have a significant impact on racing performance.’
He added: ‘Motor racing is pure adrenaline, but control is vital: our traditional markets are rather more conservative and sometimes slow moving, but control is every bit as important. We like to think that being involved in two such different environments will help develop the progressive and innovative philosophy that will drive our company forward.’
IKS International, based in Rosmalen, near 's-Hertogenbosch, supplies advanced products and services to clinical, biotechnology, pharmaceutical and microbiology laboratories worldwide.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence